Register Now: Engineering LNP's Beyond the Liver for Genetic Medicines
|Articles|August 31, 2021

Catalent Acquires Nutraceutical for $1 Billion

Catalent’s acquisition of Bettera paves the way for growth in the softgel and oral dose formulation and manufacturing market for nutraceuticals.

Catalent has reached an agreement to acquire Bettera Holdings for $1 billion, according to a company press release from Aug. 30, 2021. Bettera Holdings is a manufacturer specializing in the production of gummy, soft chew, and lozenge nutritional supplements.

This acquisition will complement Catalent’s existing softgel and oral dose formulation and manufacturing services. It will expand Catalent’s current consumer health technology platform with a wider range of technologies and ready-to-market product libraries, as well as a variety of packaging options to meet customers’ branding needs.

The acquisition is expected to close in 2021. As part of the deal, Catalent will acquire approximately 500 employees from Bettera, as well as their production facilities in California, Indiana, New Jersey, and Virginia.

“This acquisition allows us to significantly accelerate the growth of our consumer health business and offer customers access to the substantial potential in gummies, soft chews, and lozenges, which are experiencing double-digit growth,” said Aris Gennadios, president of Softgel and Oral Technologies at Catalent, in the press release. “This acquisition is a key strategic move for Catalent’s Consumer Health business, where our leadership in manufacturing technologies and formulation can offer customers more product development opportunities, and add manufacturing capacity in this dynamic and fast-growing segment.”

Source: Catalent


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Multiple green T cells surrounded by tan-colored cells, depicting immune cell activity. | Image Credit: © k_e_n - stock.adobe.com
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.